PROXYMED, INC.
 

 
 
SECURITIES AND EXCHANGE COMMISSION
UNITED STATES
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 31, 2008
PROXYMED, INC.
(Exact name of registrant as specified in its charter)
         
Florida   000-22052   65-0202059
         
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
     
1854 Shackleford Court, Suite 200    
Norcross, Georgia   30093-2924
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number including area code: (770)-806-9918
Not Applicable
(Former name or former address, if changed since last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230 .425)
 
  o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 2.01 Completion of Acquisition or Disposition of Assets
     On January 31, 2008, ProxyMed, Inc. d/b/a MedAvant Healthcare Solutions, a Florida corporation (the “Company”) completed the sale of its National Preferred Provider Network (“NPPN”) for approximately $23.5 million in cash to a subsidiary of Coalition America, Inc., a Georgia corporation (“CAI”). The sale was made pursuant to a Stock Purchase Agreement (the “Agreement”) between the Company, CAI and CCB Acquisition, LLC, a Delaware limited liability company and a subsidiary of CAI. The Agreement was previously filed as an exhibit to the Company’s Form 10-Q for the quarter ended on September 30, 2007.
     Pursuant to the terms of the Agreement, $3 million of the purchase price was placed in escrow and the purchase price is subject to a working capital adjustment. The transaction was structured as the sale of all of the equity interests in the following subsidiaries of the Company: Plan Vista Solutions, Inc. (f/k/a National Preferred Provider Network, Inc.), a New York corporation, National Network Services, LLC (f/k/a National Network Services, Inc.), a Delaware limited liability company, PlanVista Corporation (f/k/a HealthPlan Services Corporation), a Delaware corporation, Medical Resource, LLC, a Delaware limited liability company and National Provider Network, Inc., a Delaware corporation. These subsidiaries combine to comprise NPPN.
Item 8.01 Other Events
     On February 1, 2008, the Company issued a press release announcing that it had completed the sale of the business to CAI. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits
(b) Pro Forma Financial Information

2


 

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION
ProxyMed, Inc., and Subsidiaries
General Information
     The following unaudited pro forma consolidated financial information sets forth the pro forma consolidated results of operations of the Company for the nine months ended September 30, 2007 and 2006 and the twelve months ended December 31, 2006, 2005 and 2004, and the pro forma consolidated financial position of the Company as of September 30, 2007.
     The unaudited pro forma consolidated results of operations for the nine months ended September 30, 2007 and 2006 and the twelve months ended December 31, 2006, 2005 and 2004 have been derived from the Company’s historical consolidated financial information and give effect to the following transaction as if it had occurred on January 1, 2004 (the earliest period presented). In addition, the unaudited pro forma consolidated balance sheet as of September 30, 2007 has been derived from the Company’s historical consolidated financial information and gives effect to the following transaction as if it had occurred on September 30, 2007:
    Transaction — The sale of substantially all of the net assets of the Company’s Cost Containment Business to CAI in exchange for $23.5 million in cash. At closing, $3.0 million of the cash proceeds will be placed in escrow to cover possible indemnification claims, $4.0 million will be used to pay transaction costs and certain Cost Containment Business liabilities, and the remaining $16.5 million will be used to pay down a portion of the Company’s senior debt.
     The unaudited pro forma consolidated financial information has been prepared in accordance with Article 11 of Regulation S-X of the SEC and should be read in conjunction with the Company’s historical audited consolidated financial statements and unaudited interim consolidated financial statements.
     The unaudited pro forma consolidated financial information does not purport to represent what the Company’s consolidated results of operations or consolidated financial position would have been if this transaction had occurred on the date indicated and are not intended to project the Company’s consolidated results of operations or consolidated financial position for any future period or date.
     The unaudited pro forma adjustments are based on estimates and certain assumptions that the Company believes are reasonable. The unaudited consolidated pro forma adjustments and primary assumptions are described in the accompanying notes herein.

3


 

ProxyMed, Inc. and Subsidiaries
Pro Forma Consolidated Balance Sheet
As of September 30, 2007
(Unaudited)
                                 
    ProxyMed, Inc.     Cost              
    Historical     Containment     Pro Forma     Pro Forma  
    Consolidated(a)     Business(b)     Adjustments(c)     Consolidated  
    (In thousands)  
Cash and Cash Equivalents
  $ 932     $ 66     $ 20,500 (1)   $ 932  
 
                    (20,500 )(2)        
 
                    66 (3)        
Accounts Receivable Net
    12,696       7,993               4,703  
Note and Other Receivables
    86       0               86  
Inventory
    571       0               571  
Other Current Assets
    1,378       266               1,112  
 
                       
Total Current Assets
    15,663       8,325       66       7,404  
Property and Equipment, Net
    3,901       88               3,813  
Goodwill, Net
    11,870       8,176               3,694  
Purchased Technology, Capitalized Software & Other Intangible Assets, Net
    10,353       7,222               3,131  
Other Assets
    2,725       260       (1,193 )(4)     1,272  
 
                       
Total Assets
  $ 44,512     $ 24,071     $ (1,127 )   $ 19,314  
 
                       
 
                               
Accounts payable, accrued expenses and other current liabilities
    11,918       2,150       (2,000 )(5)     7,768  
Current Portion of Capital Leases
    835       0               835  
Notes Payable and Current Portion of Long-Term Debt
    18,901       0       (16,500 )(6)     1,601  
 
                    (800 )(7)        
 
                               
Deferred Revenue
    238       0               238  
Income Taxes payable
    412       0               412  
 
                       
Total Current Liabilities
    32,304       2,150       (19,300 )     10,854  
Convertible Notes
    13,137       0               13,137  
Other Long-Term Debt
    89       0       (89 )(7)     0  
Long-Term Capital Leases
    644       0               644  
Long-Term Deferred Revenue and Other Long-Term Liabilities
    380       0               380  
 
                       
Total Liabilities
    46,554       2,150       (19,389 )     25,015  
Stockholders’ Equity
                               
Preferred Stock
    0                       0  
Common Stock
    14       0               14  
Additional Paid-In Capital
    245,448       230,483       230,483 (8)     245,448  
Retained Earnings (Deficit)
    (247,504 )     (208,562 )     (230,483 )(8)     (251,163 )
 
                    66 (3)        
 
                    (1,200 )(9)        
 
                    (1,193 )(4)        
 
                    20,500 (1)        
 
                    89 (7)        
 
                       
Total Stockholder’s Equity
    (2,042 )     21,921       18,262       (5,701 )
Total Liabilities and Stockholders’ Equity
  $ 44,512     $ 24,071     $ (1,127 )   $ 19,314  
 
                       
See the accompanying notes to the unaudited pro forma consolidated financial information.

4


 

ProxyMed, Inc. and Subsidiaries
Pro Forma Consolidated
Statement of Operations
Nine Months Ended September 30, 2007
(Unaudited)
                                 
    ProxyMed, Inc     Cost              
    Historical     Containment     Pro Forma     Pro Forma  
    Consolidated (a)     Business (b)     Adjustments (c)     Consolidated  
    (In thousands except for share and per share data)  
Net Revenues:
                               
Transaction fees, cost containment services and license fees
  $ 36,382     $ 14,408             $ 21,974  
Communication devices and other tangible goods
    4,940       0               4,940  
 
                         
 
    41,322       14,408               26,914  
Cost and expenses:
                               
Cost of transaction fees, cost containment services and license fees, excluding depreciation and amortization
    9,297       4,873               4,424  
Cost of laboratory communication devices and other tangible goods, excluding depreciation and amortization
    2,785       0               2,785  
Selling, general and administrative expenses
    31,287       9,959               21,328  
Depreciation and amortization
    4,613       1,517               3,096  
Write-off of impaired assets
    21,550       14,409               7,141  
Other expense, net
    0       0               0  
(Gain)/Loss on disposal of assets
    12       0               12  
Litigation settlements
    0       0               0  
 
                       
Total Expenses
    69,544       30,758       0       38,786  
 
                       
Operating income (loss)
    (28,222 )     (16,350 )     0       (11,872 )
Other (Income), net
    0       0               0  
Interest expense, net
    3,308       0       (2,632 )(1)     676  
 
                               
Income (loss) before income taxes
    (31,530 )     (16,350 )     2,632       (12,548 )
Provision for income taxes
    0       0       0       0  
 
                       
Net Income (loss)
  $ (31,530 )   $ (16,350 )   $ 2,632     $ (12,548 )
 
                       
 
                               
Basic and diluted weighted average shares outstanding
    13,422,076       13,422,076       13,422,076       13,422,076  
Basic and diluted loss per share
  $ (2.35 )   $ (1.22 )   $ 0.20     $ (0.93 )
 
                       
See the accompanying notes to the unaudited pro forma consolidated financial information.

5


 

ProxyMed, Inc. and Subsidiaries
Pro Forma Consolidated
Statement of Operations
Nine Months Ended September 30, 2006
(Unaudited)
                                 
    ProxyMed, Inc                    
    Historical     Cost Containment     Pro Forma     Pro Forma  
    Consolidated (a)     Business (b)     Adjustments (c)     Consolidated  
    (In thousands except for share and per share data)  
Net Revenues:
                               
Transaction fees, cost containment services and license fees
  $ 42,842     $ 18,272             $ 24,570  
Communication devices and other tangible goods
    6,773       0               6,773  
 
                         
 
    49,615       18,272               31,343  
 
                               
Cost and expenses:
                               
Cost of transaction fees, cost containment services and license fees, excluding depreciation and amortization
    10,873       5,382               5,491  
Cost of laboratory communication devices and other tangible goods, excluding depreciation and amortization
    4,027       0               4,027  
Selling, general and administrative expenses
    31,930       8,733               23,197  
Depreciation and amortization
    5,554       2,208               3,346  
Write-off of impaired assets
    0       0               0  
Other expense, net
    0       0               0  
(Gain)/Loss on disposal of assets
    0       0               0  
Litigation settlements
    0       0               0  
 
                       
Total Expenses
    52,384       16,323       0       36,061  
 
                       
Operating income (loss)
    (2,769 )     1,949       0       (4,718 )
Other (Income), net
    0       0               0  
Interest expense, net
    2,239       0       (1,563 )(1)     676  
 
                               
Income (loss) before income taxes
    (5,008 )     1,949       1,563       (5,394 )
Provision for income taxes
    0       760       760 (2)     0  
 
                       
Net Income (loss)
  $ (5,008 )   $ 1,189     $ 803     $ (5,394 )
 
                       
Basic and diluted weighted average shares outstanding
    13,206,994       13,206,994       13,206,994       13,206,994  
Basic and diluted loss per share
  $ (0.38 )   $ 0.09     $ 0.06     $ (0.41 )
 
                       
See the accompanying notes to the unaudited pro forma consolidated financial information.

6


 

ProxyMed, Inc. and Subsidiaries
Pro Forma Consolidated
Statement of Operations
Twelve Months Ended December 31, 2006
(Unaudited)
                                 
    ProxyMed, Inc                    
    Historical     Cost Containment     Pro Forma     Pro Forma  
    Consolidated (a)     Business (b)     Adjustments (c)     Consolidated  
    (In thousands except for share and per share data)  
Net Revenues:
                               
Transaction fees, cost containment services and license fees
  $ 56,240     $ 23,886             $ 32,354  
Communication devices and other tangible goods
    9,222       0               9,222  
 
                         
 
    65,462       23,886               41,576  
 
                               
Cost and expenses:
                               
Cost of transaction fees, cost containment services and license fees, excluding depreciation and amortization
    13,944       6,869               7,075  
Cost of laboratory communication devices and other tangible goods, excluding depreciation and amortization
    5,389       0               5,389  
Selling, general and administrative expenses
    41,787       11,830               29,957  
Depreciation and amortization
    7,379       2,919               4,460  
Write-off of impaired assets
    0       0               0  
Other expense, net
    0       0               0  
(Gain)/Loss on disposal of assets
    12       (7 )             19  
Litigation settlements
    321       0               321  
 
                       
Total Expenses
    68,832       21,611       0       47,221  
 
                       
Operating income (loss)
    (3,370 )     2,275       0       (5,645 )
Other (Income), net
    0       0               0  
Interest expense, net
    3,240       0       (2,340 )(1)     900  
Income (loss) before income taxes
    (6,610 )     2,275       2,340       (6,545 )
Provision for income taxes
    0       887       887 (2)     0  
 
                       
Net Income (loss)
  $ (6,610 )   $ 1,388     $ 1,453     $ (6,545 )
 
                       
Basic and diluted weighted average shares outstanding
    13,207,789       13,207,789       13,207,789       13,207,789  
Basic and diluted loss per share
  $ (0.50 )   $ 0.11     $ 0.11     $ (0.50 )
 
                       
     
See the accompanying notes to the unaudited pro forma consolidated financial information.

7


 

ProxyMed, Inc. and Subsidiaries

Pro Forma Consolidated
Statement of Operations
Twelve Months Ended December 31, 2005
(Unaudited)
                                 
    ProxyMed, Inc                    
    Historical     Cost Containment     Pro Forma     Pro Forma  
    Consolidated (a)     Business (b)     Adjustments (c)     Consolidated  
    (In thousands except for share and per share data)  
Net Revenues:
                               
Transaction fees, cost containment services and license fees
  $ 67,909     $ 27,943             $ 39,966  
Communication devices and other tangible goods
    9,610       0               9,610  
 
                         
 
    77,519       27,943               49,576  
 
                               
Cost and expenses:
                               
Cost of transaction fees, cost containment services and license fees, excluding depreciation and amortization
    20,674       10,265               10,409  
Cost of laboratory communication devices and other tangible goods, excluding depreciation and amortization
    6,150       0               6,150  
Selling, general and administrative expenses
    47,962       12,826               35,136  
Depreciation and amortization
    9,305       4,421               4,884  
Write-off of impaired assets
    96,416       70,313               26,103  
Other expense, net
    0       0               0  
(Gain)/Loss on disposal of assets
    14       0               14  
Litigation settlements
    175       175               0  
 
                       
Total Expenses
    180,696       98,000       0       82,696  
 
                       
 
                               
Operating income (loss)
    (103,177 )     (70,057 )     0       (33,120 )
Other (Income), net
    (1 )     0               (1 )
Interest expense, net
    2,118 )     0       (1,218 )(1)     900  
Income (loss) before income taxes
    (105,294 )     (70,057 )     1,218       (34,019 )
Provision for income taxes
    0       0               0  
 
                       
Net Income (loss)
  $ (105,294 )   $ (70,057 )   $ 1,218     $ (34,019 )
 
                       
Basic and diluted weighted average shares outstanding
    12,707,695       12,707,695       12,707,695       12,707,695  
Basic and diluted loss per share
  $ (8.29 )   $ (5.51 )   $ 0.10     $ (2.68 )
 
                       
See the accompanying notes to the unaudited pro forma consolidated financial information.

8


 

ProxyMed, Inc. and Subsidiaries
Pro Forma Consolidated
Statement of Operations
Twelve Months Ended December 31, 2004
(Unaudited)
                                 
    ProxyMed, Inc                    
    Historical     Cost Containment     Pro Forma     Pro Forma  
    Consolidated (a)     Business (b)     Adjustments (c)     Consolidated  
    (In thousands except for share and per share data)  
Net Revenues:
                               
Transaction fees, cost containment services and license fees
  $ 73,538       26,913             $ 46,625  
Communication devices and other tangible goods
    16,708       0               16,708  
 
                         
 
    90,246       26,913               63,333  
Cost and expenses:
                               
Cost of transaction fees, cost containment services and license fees, excluding depreciation and amortization
    22,626       8,788               13,838  
Cost of laboratory communication devices and other tangible goods, excluding depreciation and amortization
    11,586       0               11,586  
Selling, general and administrative expenses
    48,023       10,967               37,056  
Depreciation and amortization
    9,763       4,123               5,640  
Write-off of impaired assets
    0       0               0  
Other expense, net
    0       0               0  
(Gain)/Loss on disposal of assets
    47       0               47  
Litigation settlements
    175       175               0  
 
                       
Total Expenses
    92,220       24,053       0       68,167  
 
                       
 
                               
Operating income (loss)
    (1,974 )     2,860       0       (4,834 )
Other (Income), net
    (134 )     0               (134 )
Interest expense, net
    1,920       0       (1,020 )(1)     900  
Income (loss) before income taxes
    (3,760 )     2,860       1,020       (5,600 )
Provision for income taxes
    40       1,115       1,115 (2)     40  
 
                       
Net Income (loss)
  $ (3,800 )     1,745     $ (95 )   $ (5,640 )
 
                       
Basic and diluted weighted average shares outstanding
    11,617,601       11,617,601       11,617,601       11,617,601  
Basic and diluted loss per share
  $ (0.33 )     0.15     $ (0.01 )   $ (0.49 )
 
                       
See the accompanying notes to the unaudited pro forma consolidated financial information.

9


 

ProxyMed, Inc. and Subsidiaries
Notes to Unaudited Pro Forma Consolidated Financial Information
I. Adjustments to unaudited pro forma consolidated balance sheet
(a) ProxyMed, Inc.
     Represents the historical unaudited consolidated balance sheet as of September 30, 2007 as reported in the Company’s Form 10-Q for the quarter ended September 30, 2007.
(b) Cost Containment Business
     Represents the elimination of the Cost Containment Business’ assets and liabilities, as reflected in the historical consolidated balance sheet of the Company as of September 30, 2007.
     The Cost Containment Business’ historical financial position is included within the Company’s Transaction Services segment for financial reporting purposes. However, the Company does maintain a separate balance sheet and subsidiary ledger for the Cost Containment Business, and the corresponding assets and liabilities of the Cost Containment Business have been allocated based on the Cost Containment Business’ subsidiary ledger and the corresponding assets and liabilities being sold. In addition, certain liabilities, such as revolving debt and other senior debt, have been transacted through the corporate accounts of the Company and therefore have not historically been reflected in the Cost Containment Business. As such, for purposes of the Cost Containment Business balance sheet, corporate debt was allocated to the Cost Containment Business on the basis of total assets of the Cost Containment Business compared to total consolidated assets.
(c) Pro Forma Adjustments
     1) At the close of the transaction, the Company will receive net proceeds of $20.5 million after the placement of $3.0 million in escrow to cover possible indemnification claims that may arise from this transaction.
     2) Represents the pay down of the Company’s senior debt, a term note related to the Cost Containment Business, certain Cost Containment Business accounts payables and transaction costs, as further described below.
     3) The Company will retain the Cost Containment Business’ cash balances at closing.
     4) This amount reflects the write off of deferred financing costs as a result of the pay down of $16.5 million of the Company’s senior debt and was estimated based on the percentage of senior debt being paid down at closing.
     5) Approximately $2.0 million of the cash proceeds will be used to pay certain accounts payable over approximately 45 days outstanding and attributable to the Cost Containment Business at closing.

10


 

ProxyMed, Inc. and Subsidiaries
Notes to Unaudited Pro Forma Consolidated Financial Information — (Continued)
     6) Approximately $16.5 million of the cash proceeds will be used to pay down a portion of the Company’s senior debt at closing.
     7) Approximately $0.9 million of the cash proceeds will be used to extinguish a Cost Containment Business note payable at closing.
     8) This amount reflects the elimination of the paid in capital and accumulated deficit related to the Company’s investment in the Cost Containment Business.
     9) Approximately $1.2 million of the cash proceeds will be used to pay transaction costs to outside advisors at closing.
II. Adjustments to unaudited pro forma consolidated statements of operations
(a) ProxyMed, Inc.
     Represents the historical unaudited consolidated statement of operations for the nine months ended September 30, 2007 and September 30, 2006, and the years ended December 31, 2006, 2005, and 2004, as reported in the Company’s Form 10-Q for the quarter ended September 30, 2007 and Form 10-K for the year ended December 31, 2006.
(b) Cost Containment Business
     Represents the elimination of Cost Containment Business’ revenues and expenses as reflected in the historical consolidated statement of operations of the Company for the nine months ended September 30, 2007, and September 30, 2006, and the years ended December 31, 2006, 2005, and 2004. The Cost Containment Business’ 2004 revenues and expenses represent only 10 months of operating results (March 2, 2004 through December 31, 2004) because the Company acquired the operations of the Cost Containment Business through its acquisition of PlanVista on March 2, 2004.
     The Cost Containment Business’ historical financial results are reported as part of the Company’s Transaction Services segment for financial reporting purposes. However, the Company does maintain a separate income statement and subsidiary ledger for the Cost Containment Business, and the corresponding operating revenues and expenses of the Cost Containment Business have been allocated based on the Cost Containment Business’ subsidiary ledger. In addition, certain expenses, including certain payroll, share-based compensation, professional fees, insurance, and other corporate overhead, have been transacted through the corporate accounts of the Company and therefore have not historically been reflected in the Cost Containment Business. As such, for purposes of the Cost Containment Business balance sheet, these expenses were allocated to the Cost Containment Business statement of operations as follows:
     a) Payroll, share based-compensation, professional fees and insurance — allocated based on Cost Containment Business revenue as a percentage of consolidated revenue.
     b) Other corporate overhead — allocated primarily based on Cost Containment Business headcount as a percentage to total consolidated headcount.

11


 

ProxyMed, Inc. and Subsidiaries
Notes to Unaudited Pro Forma Consolidated Financial Information — (Continued)
     c) Provision for income taxes have been estimated based on the historical statutory tax rate of 39% for the periods presented, where applicable.
c) Pro forma adjustments
     1) Represents adjustment to reflect interest and loan amortization expense after the payment of approximately $16.5 million of the Company’s senior debt and approximately $0.8 million of a Cost Containment Business note payable for the periods presented.
     The following table reflects the assumed interest rate and amounts of borrowings the pro forma interest expense calculation is based on and the pro-forma deferred loan amortization costs for each nine and twelve month period presented:

12


 

ProxyMed, Inc. and Subsidiaries
Notes to Unaudited Pro Forma Consolidated Financial Information — (Continued)
                                 
                    Pro-forma interest     Pro-forma interest  
            Amount of     expense — nine     expense — twelve  
Interest expense (in thousands)   Total rate     borrowing     month periods     month periods  
Senior debt
    10.0%   $ 1,690     $ 127     $ 169  
Convertible debt
    4.0%     $ 13,137     $ 394     $ 525  
Other
    7.0%     $ 1,479     $ 78     $ 104  
 
                           
 
                               
Total interest expense
                  $ 599     $ 798  
 
                               
Amortization of deferred financing costs (in thousands)
                               
 
                               
Senior debt
                  $ 77     $ 102  
 
                           
 
                               
Total amortization of deferred financing costs
                  $ 77     $ 102  
 
                           
 
                               
Total interest expense and amortization of deferred financing costs
                  $ 676     $ 900  
 
                           
                 
    ProxyMed, Inc. Historical    
Interest and amortization expense (in thousands)   Consolidated   Pro forma Adjustment
Nine months ended September 30, 2007
  $ 3,308     $ 2,632  
Nine months ended September 30, 2006
  $ 2,239     $ 1,563  
Twelve months ended December 31, 2006
  $ 3,240     $ 2,340  
Twelve months ended December 31, 2005
  $ 2,118     $ 1,218  
Twelve months ended December 31, 2006
  $ 1,920     $ 1,020  
     2) Provision for income tax is eliminated due to a remaining net loss after the elimination of the Cost Containment Business and the pro forma adjustments.

13


 

(d) Exhibits:
     
Exhibit No.   Description
 
99.1
  Press Release dated February 1, 2008

14


 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ProxyMed, Inc.
(registrant)
 
 
February 5, 2008  By:   /s/ John G. Lettko   
    John G. Lettko, President   
       and Chief Executive Officer   
 

15